Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$9.00 USD
-0.24 (-2.60%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $9.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 21 - 40 ( 132 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IgAN sNDA Advances, FSGS No Go While Workforce Reduction Hits
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for TVTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari Fizzled A Bit in 3Q23, But Continue To Receive Positive Doc Feedback
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The IgAN Era Continues, While Xphozah Makes A Splash Ahead Of Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney Week 2023 - Gearing Up For What''s New in Glomerular Disease
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney KOL Check: Traversing Through The PROTECT Data [Call Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney KOL Check - Traversing Through The TVTX PROTECT Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Narrow Miss on Confirmatory eGFR Total Slope Endpoint Complicates Path to Full Approval for FILSPARI; Cut PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PROTECT Readout Mixed, But Stock Reaction Appears Overdone
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: FILSPARI to Accelerate in 2H; Topline eGFR Data by Early 4Q; HCU Phase 3 by YE23; Trim PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari Launch Gets More Interesting As We Go; PROTECT Pulls Forward
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving On With MIRM -- TVTX Divests Bile Acid Franchise
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Commercial Biotech Preview: Could 2Q23 Reporting Help Restart a Rally?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Survey Says... Latest Nephrologist Survey Looks At IgAN Prescribing Trends
Provider: Wedbush Securities Inc.
Analyst: CHICO L